Alvogen, Inc. and partner Natco Pharma Limited have been handed a major setback in their attempt launch a generic version of AbbVie’s Imbruvica (ibrutinib) tablets ahead of patent expiry, with a US district court ruling that the Icelandic firm’s proposed abbreviated new drug application infringes certain of the originator’s patent claims and that patent claims are not invalid.
Alvogen Imbruvica Ruling Set To Push AbbVie’s Monopoly To 2032
Icelandic Firm And Partner Natco Fail With Invalidity Challenges
Alvotech and Natco have failed to persuade a US court that certain of AbbVie’s IP shielding its Imbruvica blockbuster is invalid. In response, the originator said that it did not anticipate generic competition to its branded oral therapy for treating forms of cancer until March 2032, assuming pediatric exclusivity is granted.
More from Generics
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.